Projects

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis

Groups and Associations Partha Sarathi Roy  1 , Shiji John  1 , Sadashiv Karankal  2 , Sadhana Kannan  2 , Preeti Pawaskar  1 , Jayanta Gawande  1 , Bhausaheb Bagal  1 , Navin Khattry  1 , Manju Sengar  1 , Hari Menon  1 , Sumeet Gujral  3 , Reena Nair  4
Indian J Med Paediatr Oncol 2013

Abstract

Background: Rituximab (Mabthera™) have been in use in India since 2000. A biosimilar molecule of rituximab (Reditux™) was approved in India in 2007. This retrospective audit was done to compare the efficacy and safety of Mabthera™ with Reditux™.

Book